MedPath

Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins

Generic Name
Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins
Drug Type
Biotech
Unique Ingredient Identifier
3ME9TTI5QB
Background

Adipose mesenchymal stem cells (AMSCs) are MSCs derived from adipose tissue, which is more accessible and less painful than stem cells extracted from most other sources. Autologous stem cells are those derived from a patient’s own cells while allogeneic stem cells are derived from that of a donor. Lipoaspiration, also known as liposuction, is a possible method for extraction. This is followed by purification and expansion of the cells in vitro.

These AMSCs are multipotent, with the capability of forming different tissues, some of which include bone, muscle, neural, and chondrocyte. This explains why AMSCs have been utilized in repairing craniofacial bone defects. They also have potential in treatment of scarred vocal folds.

Clinical Trials
Related News

Brain Hemorrhage Treatment Market Expected to Grow Significantly by 2032 as AI Solutions Gain FDA Approval

• The brain hemorrhage treatment market is projected to experience substantial growth through 2032, driven by an aging population and increasing prevalence of risk factors such as hypertension and traumatic brain injuries. • Recent FDA approvals for AI-based diagnostic tools, including JLK-LVO and Heuron ICH, mark significant advancements in early detection and treatment of brain hemorrhages. • Several pharmaceutical companies including Baxter, Pfizer, and Novartis are developing promising pipeline therapies such as tissue plasminogen activator, alteplase, and BAF312 to address the significant unmet needs in brain hemorrhage treatment.

Hope Biosciences Receives FDA Authorization for Phase II JIA Stem Cell Trial

• Hope Biosciences Research Foundation received FDA authorization to begin a Phase II clinical trial using HB-adMSCs for pediatric patients with juvenile idiopathic arthritis (JIA). • The trial will enroll 66 participants aged 2-16 years and will assess the safety and efficacy of adipose-derived mesenchymal stem cells in treating JIA. • This randomized, double-blind, crossover study will evaluate the impact of HB-adMSCs on the quality of life for children affected by JIA over a 72-week period. • HBRF has obtained FDA authorization for more than 40 clinical protocols, remaining the only entity exploring the effects of sustained adult stem cell application.

Advancements in Traumatic Brain Injury Clinical Trials Highlighted for 2024

The latest report on Traumatic Brain Injury (TBI) clinical trials for 2024 showcases significant progress in developing novel therapies, with key companies and emerging drugs poised to impact the TBI market. The report emphasizes the importance of ongoing research and the potential of innovative treatments to improve patient outcomes.

Hope Biosciences' Stem Cell Therapy Shows Promise in Phase II MS Trial

• Hope Biosciences' HB-adMSCs demonstrated statistically significant improvements in physical and mental health for relapsing-remitting MS patients compared to placebo. • The Phase II trial (NCT05116540) involved six intravenous infusions of 200 million stem cells over 32 weeks, totaling 1.2 billion cells per patient. • The HB-adMSC group showed significant improvement in Physical Health Composite Scores (p<0.0001) and Mental Health Composite Scores (p<0.0042) versus placebo. • The treatment was found to be safe and tolerable, suggesting potential for HB-adMSCs in managing multiple sclerosis.

Hope Biosciences' Stem Cell Therapy Shows Promise in Phase II MS Trial

• Hope Biosciences' HB-adMSCs demonstrated statistically significant improvements in physical and mental health for relapsing-remitting MS patients. • The Phase II trial met its primary endpoint, showing a significant difference compared to placebo in MS Quality of Life scores. • Treatment with HB-adMSCs was found to be safe and tolerable, paving the way for potential future applications in autoimmune diseases. • The study involved six intravenous infusions of 200 million stem cells over 32 weeks, totaling 1.2 billion cells per patient.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy